• Policy
• Taiwanese PharmaEssentia got a business license
• by Lee, Tak-Sun Nov 5, 2021 05:24am

• Policy
• Gov needs to maintain patient benefits to the public
• by Lee, Jeong-Hwan Nov 5, 2021 05:23am

• Policy
• The HIRA proceeds to improve the mediation system
• by Lee, Hye-Kyung Nov 4, 2021 05:56am

• Policy
• MFDS to support Phase III trials of domestic COVID-19 Txs
• by Lee, Tak-Sun Nov 4, 2021 05:56am

• Policy
• NA asks NHIS to introduce the reference pricing system
• by Lee, Hye-Kyung Nov 4, 2021 05:55am

• Policy
• Refund RSA may be set higher than the lowest price
• by Lee, Jeong-Hwan Nov 4, 2021 05:55am

• Policy
• Finding a system that suppresses the use of expensive drugs
• by Kim, Jung-Ju Nov 4, 2021 05:55am

• Policy
• HIRA deletes GDP phrase but maintains current ICER threshold
• by Lee, Hye-Kyung Nov 3, 2021 05:47am

• Policy
• The new system doesn't stop benefits for anticancer drugs
• by Lee, Jeong-Hwan Nov 3, 2021 05:47am

• Policy
• The number of licenses for Rx drugs in October exceeded 100
• by Lee, Tak-Sun Nov 3, 2021 05:46am